Effects of chemotherapy combined with immunotherapy for non-small cell lung cancer with BRAF-mutations: a retrospective study
- 1 January 2025
- journal article
- Published by e-Century Publishing Corporation in American Journal of Cancer Research
- Vol. 15 (8) , 3533-3545
Abstract
Objectives: To characterize the clinical features of non-small cell lung cancer (NSCLC) harboring BRAF mutations and to evaluate the effects of first-line chemotherapy combined with immunotherapy versus targeted therapy. Methods: We retrospectively reviewed patients with BRAF-mutated NSCLC diagnosed between January 2017 and June 2023 at the Affiliated Cancer Hospital of Zhengzhou University. A total of 120 patients were included, with an overall BRAF mutation frequency of 0.9%. Among the mutations detected, the Val600Glu (V600E) substitution constituted 54.2% of cases. Clinical characteristics were compared between V600E and non-V600E subgroups, and treatment efficacies were analyzed. Results: Ninety-five patients received first-line treatment. The overall median progression-free survival (mPFS) was 8.77 months, and the median overall survival (mOS) was 13.30 months. First-line chemotherapy combined with immunotherapy resulted in longer mPFS (17.17 vs. 9.03 months, P = 0.573) and mOS (17.50 vs. 16.07 months, P = 0.376) compared with targeted therapy using BRAF and MEK inhibitors. In addition, patients with V600E mutations exhibited a trend toward longer mPFS compared to those with non-V600E mutations (9.73 vs. 6.77 months, P = 0.244). Conclusions: Chemotherapy combined with immunotherapy may represent a promising first-line treatment strategy for NSCLC patients with BRAF mutations. Although the number of patients receiving subsequent lines of treatment was limited and their prognosis poor, a regimen of BRAF and MEK inhibitors appeared to offer therapeutic advantages in this setting.Keywords
This publication has 33 references indexed in Scilit:
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASNature, 2017
- Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutationCancer Medicine, 2017
- Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialThe Lancet Oncology, 2016
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic InhibitionCancer Cell, 2015
- Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondNature Reviews Cancer, 2014
- Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohortsBritish Journal of Cancer, 2014
- Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutationsAnnals of Oncology, 2013
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Mutations of the BRAF gene in human cancerNature, 2002